{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:34:41Z","timestamp":1791329681461,"version":"4.3.1"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Rapid expansion of the therapeutic landscape for metastatic castration-resistant prostate cancer (mCRPC) has increased the complexity of treatment selection and sequencing. However, large, contemporary studies describing treatment patterns and attrition rates in clinical treatment of mCRPC are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate treatment patterns and attrition rates in patients with mCRPC from 2021 to 2025.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective multicenter cohort study used the US-based, electronic health record\u2013derived, deidentified Flatiron Health Research Database to identify patients with mCRPC who initiated first-line therapy between January 1, 2021, and June 30, 2025, at approximately 280 centers, primarily community oncology practices.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Year of first-line treatment initiation and types of treatment for mCRPC.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n First- through fifth-line treatment and attrition rates were summarized using frequencies and percentages into respective categories: androgen receptor pathway inhibitors (ARPIs), taxanes, poly (adenosine diphosphate\u2013ribose) polymerase inhibitors (PARPIs), platinum-based therapies, lutetium Lu 177\u2013prostate-specific membrane antigen 617 (Lu-177)\u2013based therapies, radium Ra 223, sipuleucel-T, immunotherapy, and other.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 27\u202f979 patients in the dataset, 5096 with mCRPC initiating first-line therapy were included in the analysis. The median age was 75 (IQR, 68-82) years. Overall, 2731 patients (53.6%) received second-line treatment and 1334 (26.2%) received third-line treatment. ARPI was the most common first-line (4041 of 5096 [79.3%]) and second-line (1123 of 2731 [41.1%]) treatment, with decreasing use in subsequent lines. Taxane use increased from 637 of 5096 patients (12.5%) in first-line treatment to 953 of 2731 (34.9%) in second-line treatment and became the most common third-line treatment (485 of 1334 [36.4%]). Overall, 2192 patients (43.0%) received taxane-based therapies. Use of Lu-177 increased progressively from 113 of 5096 patients (2.2%) in first-line treatment to 71 of 226 patients (31.4%) by fifth-line initiation. PARPI use was limited and peaked at 99 of 1334 patients (7.4%) in third-line treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with mCRPC, only slightly more than half of patients received second-line treatment, and attrition rose significantly across subsequent treatment lines. ARPIs and taxanes remained the most common first-line treatments, with increased use of Lu-177 and PARPIs in later treatment lines. These findings highlight the evolving complexity of mCRPC management and significant attrition with later lines, underscoring the need for optimized sequencing strategies, more efficacious frontline therapies, and interventions to improve access.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.20750","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:32:54Z","timestamp":1782747174000},"page":"e2620750","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Gabriel","family":"Hooper","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjung","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Nandakumar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Gebrael","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Irem","family":"Ozay","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Hardy","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Campbell","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan G.","family":"Murdock","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnam","family":"Goel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay Mathew","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra O.","family":"Sokolova","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Internal Medicine, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"16","key":"zoi260576r1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70037","article-title":"Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.","volume":"131","author":"Saeed","year":"2025","journal-title":"Cancer"},{"issue":"15","key":"zoi260576r2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"9747","key":"zoi260576r3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"zoi260576r4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi260576r5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer.","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi260576r6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy.","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260576r7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer.","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi260576r8","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update.","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi260576r9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer.","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260576r10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer.","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260576r11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10398","key":"zoi260576r12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"zoi260576r13","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer.","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi260576r14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer.","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"10459","key":"zoi260576r15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"zoi260576r16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population.","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"zoi260576r17","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1093\/oncolo\/oyad046","article-title":"Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study.","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"zoi260576r18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.euf.2025.10.011","article-title":"Real-world treatment patterns and survival in metastatic castration-resistant prostate cancer: a systematic review of observational studies.","volume":"12","author":"Raval","year":"2026","journal-title":"Eur Urol Focus"},{"issue":"3","key":"zoi260576r19","doi-asserted-by":"publisher","first-page":"146.e13","DOI":"10.1016\/j.urolonc.2022.11.019","article-title":"A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 - 2018.","volume":"41","author":"Moldaver","year":"2023","journal-title":"Urol Oncol"},{"issue":"5","key":"zoi260576r20","doi-asserted-by":"publisher","first-page":"192.e1","DOI":"10.1016\/j.urolonc.2022.01.009","article-title":"Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.","volume":"40","author":"Shayegan","year":"2022","journal-title":"Urol Oncol"},{"issue":"8","key":"zoi260576r21","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors.","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"8","key":"zoi260576r23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups.","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"10","key":"zoi260576r25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/CAD.0000000000001756","article-title":"Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE study.","volume":"36","author":"Papet","year":"2025","journal-title":"Anticancer Drugs"},{"issue":"6","key":"zoi260576r26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/COC.0000000000001087","article-title":"Risk factors for early treatment discontinuation due to toxicity among patients with metastatic castration-resistant prostate cancer receiving androgen receptor-targeted therapy.","volume":"47","author":"Chakrani","year":"2024","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"zoi260576r27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.clgc.2023.04.014","article-title":"Treatment patterns, clinical outcomes, health care resource utilization and costs in older patients with metastatic castration-resistant prostate cancer in the United States: an analysis of SEER-Medicare data.","volume":"21","author":"Swami","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"zoi260576r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102499","article-title":"Treatment discontinuation in metastatic castration-resistant prostate cancer (mCRPC) patients treated with lutetium-177 (177Lu)-PSMA-617: a retrospective real-world study.","volume":"24","author":"Samadi","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"26","key":"zoi260576r29","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer.","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi260576r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102188","article-title":"Treatment patterns and survival outcomes among androgen receptor pathway inhibitor-experienced patients with metastatic castration-resistant prostate cancer.","volume":"22","author":"Narayan","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"zoi260576r32","doi-asserted-by":"publisher","first-page":"S1745","DOI":"10.1016\/j.annonc.2025.09.105","article-title":"LBA89: a randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21.","volume":"36","author":"Chi","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi260576r34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).","volume":"28","author":"Armstrong","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"zoi260576r35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline.","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260576r36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer.","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi260576r37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14796694.2025.2470616","article-title":"Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe.","volume":"21","author":"Castro","year":"2025","journal-title":"Future Oncol"},{"issue":"7","key":"zoi260576r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers.","volume":"7","author":"Hage Chehade","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi260576r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103129","article-title":"Comparative therapeutic efficacy and safety of first-line and second-line therapies for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.","volume":"81","author":"Jiang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"zoi260576r40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review.","volume":"87","author":"Francini","year":"2025","journal-title":"Eur Urol"},{"issue":"10","key":"zoi260576r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.34968","article-title":"Receipt of PARP inhibitors in patients with metastatic prostate cancer harboring BRCA1\/2 alterations.","volume":"8","author":"Ostrowski","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260576r42","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"zoi260576r43","doi-asserted-by":"publisher","first-page":"S1627","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition).","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260576r44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"zoi260576r22","unstructured":"Database characterization guide. Flatiron Health. Published March 18, 2025. Accessed October 10, 2025. https:\/\/flatiron.com\/database-characterization"},{"key":"zoi260576r24","unstructured":"R: A Language and Environment for Statistical Computing. Version 4.5.1. R Foundation for Statistical Computing. Accessed October 16, 2025. https:\/\/www.R-project.org\/"},{"key":"zoi260576r31","unstructured":"FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. US Food and Drug Administration. Accessed April 12, 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"},{"key":"zoi260576r33","unstructured":"NCCN clinical practice guidelines in oncology prostate cancer. National Comprehensive Cancer Network. Accessed November 7, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850948\/hooper_2026_oi_260576_1782852609.72526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:28:48Z","timestamp":1782854928000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.20750","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}